Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854050 | 0.85 | — | — | |
| SCHEMBL19862682 | 0.83 | — | — | |
| SCHEMBL13137642 | 0.83 | HTR1A (0.34) | NLRP3ALDH1A1 | |
| SCHEMBL12456989 | 0.80 | NLRP3 (0.39) | NLRP3TRPA1KDM4ECYP3A4ALDH1A1 | |
| SCHEMBL420201 | 0.78 | — | — | |
| SCHEMBL16087968 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL10771596 | 0.75 | — | — | |
| SCHEMBL597046 | 0.73 | NLRP3 (0.50) | NLRP3KDM4ECYP3A4ALDH1A1LMNA | |
| SCHEMBL7112088 | 0.73 | — | — | |
| SCHEMBL15999550 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736892-A2 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | Cerus Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3852817-B1 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | CERUS CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | CERUS CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250216379-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | CERUS CORP (US) | 2025-07-03 | — | — | US | disclosed |
| US-12282015-B2 | Systems and methods for testing and screening using compound bound substrates | CERUS CORPORATION (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119701114-A | Methods and kits for preparing pathogen inactivated whole blood | 塞鲁斯公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024221045-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2024-10-31 | — | — | WO | disclosed |
| CN-113271975-B | Methods and kits for preparing pathogen inactivated whole blood | 塞鲁斯公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-110268264-B | System and method for testing and screening substrates using compound binding | 塞鲁斯公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230408490-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | CERUS CORPORATION | 2023-12-21 | — | — | US | disclosed |
| EP-1085880-A2 | USE OF ALKYLATING COMPOUNDS FOR INHIBITING PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS | Cerus Corporation (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1045704-A1 | METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS | Cerus Corporation (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1021414-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093725-A | A BINDER FOR DEACTIVATING PATHOGENS IN A BLOOD SAMPLE TO BIND NUCLEIC ACID BY COVALENT LINKAGE | CERUS CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1005531-A2 | METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF | Cerus Corporation (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999063981-A2 | USE OF ALKYLATING COMPOUNDS FOR INHIBITING PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS | CERUS CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999034839-A1 | METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS | CERUS CORPORATION (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999003976-A2 | METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF | CERUS CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998030545-A9 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998030545-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | PRF1, CFD, F5 | NLRP3 84/4885TRPA1 4277/4885KDM4E 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.